{
    "pmcid": "8906176",
    "qa_pairs": {
        "What future strategy is suggested to potentially enhance the neutralizing potency of monobodies?": [
            "Multimerization of monobodies",
            "Increasing the size of monobodies",
            "Using a different bacterial expression system",
            "Targeting a different domain of the spike protein"
        ],
        "What method was used to enhance the binding affinity of monobodies to the SARS-CoV-2 spike protein's RBD?": [
            "TRAP display method",
            "Phage display method",
            "Yeast surface display",
            "Ribosome display"
        ],
        "What specific mutations in the RBD affected the binding affinity of the C4 and C4-AM2 monobodies?": [
            "E484K and L452R",
            "N501Y and D614G",
            "K417N and T478K",
            "P681H and S477N"
        ],
        "What was the IC50 value of the C4-AM2 monobody against the wild-type SARS-CoV-2 virus?": [
            "46 pM",
            "30 pM",
            "60 pM",
            "75 pM"
        ],
        "Which specific monobody was identified as having an exceptionally high affinity for the RBD of the SARS-CoV-2 B.1.1 variant?": [
            "C4-AM2 monobody",
            "C5-AM2 monobody",
            "D4-AM2 monobody",
            "E4-AM2 monobody"
        ]
    }
}